International study reveals genetic 'spelling mistakes' linked to some cancers

Share this content:

More than 80 genetic “spelling mistakes” that may indicate an increased risk of breast, prostate, and ovarian cancers were revealed in the findings of a large, international research study within the framework of the European Union (EU) Network Collaborative Oncological Gene-environment Study (COGS). For the first time, researchers have a relatively clear picture of the total number of genetic alterations that can be linked to these cancers. Ultimately they hope to be able to calculate the risk of individual cancers, to better understand how they develop and to be able to tailor new treatments.

The main study findings are published in a special issue on genetic risk factors for cancer in the prestigious scientific journal Nature Genetics. Originating from COGS, an EU-based consortium that includes more than 160 research groups from all over the world, the studies included 100,000 patients with breast, ovarian, or prostate cancer and 100,000 healthy participants from the general population.

The scientists performed genetic analyses on all study participants. The composition of the nitrogen bases A, G, C and T was studied on 200,000 selected sections of the DNA strand. When cancer patients had significantly different compositions compared with healthy control subjects, the differences were considered to be relevant to risk of disease. The alterations can be described as a genetic spelling mistake, where A, G, C, or T have been replaced with another letter. This spelling mistake is called single nucleotide polymorphism (SNP, pronounced “snip”).

For breast cancer, the researchers found 49 genetic typos or SNPs, which is more than double the number previously found. In the case of prostate cancer, researchers discovered another 26 deviations, which means that a total number of 78 SNPs may be linked to the disease. For ovarian cancer, eight new relevant SNPs were found.

“We're now on the verge of being able to use our knowledge to develop tests that could complement breast cancer screening and take us a step closer to having an effective prostate cancer screening program,” said Professor Doug Easton, PhD, of the University of Cambridge, United Kingdom, who has led several of the presented studies.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs